Instil Bio (TIL) Common Equity (2020 - 2026)

Instil Bio has reported Common Equity for 7 years, with the latest figure at $107.4 million in Q2 2026.

• On a quarterly basis, Common Equity fell 18.45% year-over-year to $107.4 million in Q2 2026; TTM through Jun 2026 was $107.4 million, a 18.45% decrease from a year earlier, with the FY2025 full-year figure at $113.9 million, down 32.8% from the prior year.
• Common Equity was $107.4 million for Q2 2026 at Instil Bio, down from $110.7 million in the prior quarter.
• The five-year high for Common Equity was $508.6 million in Q1 2022, with the low at $107.4 million in Q2 2026.
• Average Common Equity over 5 years is $238.0 million, with a median of $200.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Common Equity sank 43.0% in 2023, then dropped 18.45% in 2026.
• Over 5 years, Common Equity stood at $363.6 million in 2022, then sank by 37.89% to $225.8 million in 2023, then decreased by 24.97% to $169.4 million in 2024, then sank by 32.8% to $113.9 million in 2025, then retreated by 5.7% to $107.4 million in 2026.
• The last three Common Equity figures came in at $107.4 million (Q2 2026), $110.7 million (Q1 2026), and $113.9 million (Q4 2025), per Business Quant data.